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Abstract  
We analyzed 5,484 close contacts of COVID-19 cases from Italy, all of them tested for SARS-CoV-2 infection. We 
found an infection fatality ratio of 2.2% (95%CI 1.69-2.81%) and identified male sex, age >70 years, 
cardiovascular comorbidities, and infection early in the epidemics as risk factors for death. 
 
Main text 
 
The proportion of infections resulting in a fatal outcome, known as infection-fatality ratio (IFR), and the 
associated risk factors are still poorly quantified for the newly emerged SARS-CoV-2 [1,2]. Estimates of the IFR 
are key to evaluate the health impact of epidemics and the effectiveness of control strategies [3,4]. Estimates of 
the IFR conditioned on age, sex, and comorbidities are useful to project the expected number of deaths in 
populations characterized by different demographics and prevalence of chronic diseases, and to identify the 
most vulnerable segments of the population.  
 
Given the high proportion of asymptomatic and pauci-symptomatic SARS-CoV-2 infections [5,6], it is difficult to 
estimate the IFR from surveillance data [2-4]. In addition, the proportion of ascertained cases over all infections 
can change dramatically across regions and over time [3,4]. The increasing availability of serological data can 
assist precise and direct measurements of the IFR. Literature estimates available so far are highly variable 
(ranging from 0.07% to 1.6%) [1-3,7,8], based on small non-random samples [8], data pooled from 
heterogeneous populations [1-3,7], or derived through modeling analyses [3]. 
 
In this study, we compute stratified IFR values for SARS-CoV-2 by combining different data on the same group of 
individuals. The study population comprises contacts of COVID-19 cases identified through contact tracing 
operation conducted in Lombardy, Italy between February and April 2020. For these subjects, laboratory results 
on reverse transcription polymerase chain reaction (RT-PCR) from nasopharyngeal swabs administered during 
the contact tracing activity are analyzed. This data is complemented with the results of an ongoing serological 
survey on the same group of individuals started on April 16, 2020. Finally, we also collected information on the 
presence of comorbidities (respiratory, cardiovascular, metabolic and oncological) and clinical outcomes of each 
case reported in the Lombardy linelist of COVID-19 patients (last update: June 8, 2020).  
 
Data analyzed here represent a selection from a database of 62,881 contacts of COVID-19 cases. We selected 
only the contacts belonging to clusters (i.e., groups of contacts identified by one positive index case) where all 
individuals were tested against SARS-CoV-2 infection either through nasal swabs during the contact tracing 
operations or IgG serological testing retrospectively. In fact, to economize the saturated testing resources in 
Lombardy, from February 26, 2020 onward (i.e., shortly after the detection of the first locally-transmitted 
COVID-19 case in Italy) only symptomatic cotnacts of COVID-19 cases were tested via RT-PCR. On April 16, 2020, 
the regional health authorities started a serological survey aiming at completing the ascertainment of SARS-
CoV-2 infections among all close contacts identified for each confirmed case. To avoid possible biases, we 
excluded index cases, who were often identified because of their symptoms and were thus possibly at higher 
risk of severe disease, from our analysis. The accuracy of IgG testing and RT-PCR used in our sample was 
assessed in [9,10]. The IFR was computed as the proportion of deaths occurred among all SARS-CoV-2 positive 
contacts identified in the considered sample, here defined as subjects with at least one laboratory confirmation 
of their infection.  
 
Overall, we analyzed 5,484 contacts (median age 50, IQR 30-61; 43.7% males), of which 1,364 (25%) were 
tested only by an RT-PCR assay targeting different SARS-CoV-2 genes during the contact tracing activities [9]; 
3,493 (64%) only by a serological assay for IgG neutralizing antibodies against S1/S2 antigens [10] at least a 
month after the reporting date of their index case; 627 (11%) were tested both with RT-PCR and serological 
assays. Out of 5,484 analyzed individuals, 2,824 resulted positive to SARS-CoV-2 (median age 53, IQR 34-64; 
43.2% males), and among them 62 died with a COVID-19 diagnosis (median age 79, IQR 74-83; 53.2% males).  
 
We found an IFR of 18.35% (95%CI 12.65-25.28%) for individuals aged 80 years or more, 3.62% (95%CI 2.45-
5.13%) for those aged 60-79 years, and 0.16% (95%CI 0.03-0.48%) for those younger than 60 years (Table 1 and 
Figure S1 in Appendix). No deaths were recorded among individuals below 50 years of age. The overall IFR was 
estimated at 2.2% (95%CI 1.69-2.81%), but it decreased over time, ranging from 2.95% (95%CI 2.14-3.97%) for 
patients associated with clusters identified before March 16, 2020 (the median date of confirmation among 
index cases in the considered clusters) to 1.33% (95%CI 0.79-2.09%) for clusters identified afterwards. Such a 
difference was especially marked among infections over 80 years of age (IFR: 30.4% vs 8.1%). In our sample, 51 
out of 62 deaths occurred in patients were affected by cardiovascular diseases. The IFR for infections with this 
comorbidity was at 16.14% (95%CI 12.26-20.67%). The overall IFR was 50% higher in males (2.70% vs 1.80%). 
 
To identify the risk factors associated with fatal outcomes after SARS-CoV-2 infection we applied a generalized 
linear model (GLM with logit link) relating the observed outcome (death vs. survival) to the sex and the age 
group (0-59, 60-69, 70-79, 80+ years) of exposed individuals, to the presence of comorbidities (none, 
cardiovascular, others) and to the epidemic period associated with the observed outcomes (before or after 
March 16, 2020). We found that individuals younger than 70 years were at a significantly lower risk of death 
after infection compared to older patients (Tukey test: p-value<0.001); females were 55.2% less likely to die 
compared to males (95%CI 31.6-97.0%; Tukey test: p -value<0.001); the relative risk of death was 5.6 times 
higher for patients affected by cardiovascular comorbidities (95%CI 1.2-55.3) compared to otherwise healthy 
individuals, although this difference was not statistically significant (Tukey test: p -value=0.29). Finally, the risk of 
death was 62% lower (95%CI 31-80%; Tukey test: p-value<0.001) during the second phase of the epidemic 
(Table S1 in Appendix). 
 
Our estimate of the overall IFR (2.2%) is consistent with the range of estimates obtained for Spain (from 1% to 2% 
[2]), but higher than estimates reported in other studies [1-3,7,11]. Such differences may be due to the high 
proportion of older individuals in the Lombardy population (28.7% of people older than 60 years), or differences 
in the prevalence of chronic diseases. In particular, more than 80% of the deaths recorded in our sample 
occurred in patients with cardiovascular diseases, which represented the most common comorbidity among 
patients hospitalized in the early phase of the Italian epidemic [12]. Due to the limited sample size we are 
unable to provide solid estimated of the IFR stratified both by age and comorbidities. Finally, the high average 
IFR we found may also be related to the specific area and time period considered here, mirroring a health 
system under a severe strain because of the rapid, massive increase of patients requiring intensive care [12]. 
These conditions combined with the initial scant evidence on appropriate treatments of disease may well have 
affected the health system capacity to cope with severe cases. This hypothesis is supported by the remarkable 
difference in the IFRs estimated for clusters identified before and after March 16 (2.95% vs. 1.33%).  
The age distribution of our sample reflects that of the Lombardy population (Figure S2 in Appendix). However, 
the data considered in this study represent a sample of individuals who were exposed to COVID-19 cases. 
Therefore, the reported infection attack rates cannot be considered as representative of the immunity level 
caused by SARS-CoV-2 in this region.  
A limitation of the presented analysis is that infections were identified in two different periods of time and using 
different tests (RT-PCR and IgG serological assays). In our sample, all contacts were followed for symptom onset, 
but while symptomatic individuals were tested by PCR shortly after their index case was identified, IgG 
serological tests were performed on individuals more than 1 month after their identification as contacts. These 
features minimize potential biases related to either the identification of infections and deaths or to 
seroconversion delays. However, out of 327 contacts tested by both RT-PCR and serology, 137 resulted negative 
to RT-PCR and positive to serology (Table S2 in Appendix). We explored to what extent failures in RT-PCR testing 
may impact estimates on the overall IFR, by considering a worst-case scenario where 41.9% (i.e. 137/327) of 
negative contacts who were tested with RT-PCR only (i.e., 732) are assumed to be positive. The estimated IFR in 
this case becomes 2.04% (95%CI 1.57-2.60%).  
The estimates provided here can be considered a robust representation of the IFR during the COVID-19 
epidemic in Lombardy - the most affected Italian region [9,12]. These results can be instrumental in evaluating 
the expected burden of possible future outbreaks. The indication on the key factors that are strongly influencing 
the SARS-CoV-2 IFR could be used to inform targeted interventions and possible future COVID-19 vaccination 
campaigns.  
Tables and Figures 
 
 Contacts SARS-CoV-2 positive Deaths Infection fatality ratio (%) 
Total 5,484 2,824 62 2.20 (95%CI 1.69-2.81) 
Sex     
Males 2,398 1,220 33 2.70 (95%CI 1.87-3.78) 
Females 3,086 1,604 29 1.81 (95%CI 1.21-2.59) 
Age     
0-19y 692 304 0 0 (95%CI 0-1.21) 
20-49y 1,951 885 0 0 (95%CI 0-0.42) 
50-59y 1,241 648 3 0.46 (95%CI 0.1-1.35) 
60-69y 867 494 7 1.42 (95%CI 0.57-2.9) 
70-79y 485 335 23 6.87 (95%CI 4.4-10.12) 
80+ 248 158 29 18.35 (95%CI 12.65-25.28) 
Comorbidity     
None 122 113 1 0.88 (95%CI 0.02-4.83) 
Cardiovascular # 350 316 51 16.14 (95%CI 12.26-20.67) 
Respiratory system # 50 49 8 16.33 (95%CI 7.32-29.66) 
Oncological # 106 92 11 11.96 (95%CI 6.12-20.39) 
Diabetes  and other metabolic # 93 79 13 16.46 (95%CI 9.06-26.49) 
Unknown 4,947 2,335 9 0.39 (95%CI 0.18-0.73) 
Epidemic period     
Before March 16, 2020 2,696 1,423 42 2.95 (95%CI 2.14-3.97) 
After March 16, 2020 2,721 1,358 18 1.33 (95%CI 0.79-2.09) 
Unknown 67 43 2 4.65 (95%CI 0.57-15.81) 
# include patients with other comorbidities 
Table 1. Sample description and IFR estimates by sex, age group, comorbidities, and epidemic period.  
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Appendix 
 
Materials and Methods 
 
Data 
 
The data analyzed in this study were taken from a database providing, among other details, information on sex, 
age, presence of comorbidities for close case contacts, the results of RT-PCR tests and serological tests (if any), 
and the clinical outcome of positive cases. In particular, the database was built by combining: 
i) data records collected during the contact tracing activities conducted between February 21 and April 16, 2020 
by the Lombardy healthcare agencies; 
ii) results of RT PCR assays on nasopharyngeal swabs mainly administered to symptomatic contacts short after 
their identification during contact tracing; 
iii) results from serological assays collected within a seroprevalence study started on April 16, 2020 and not yet 
completed, which mainly targets case contacts who were not tested by RT-PCR or resulted negative to RT-PCR;  
iv) information (updated to June 8, 2020) on the clinical outcome of patients as available in the linelist of all 
COVID-19 laboratory confirmed cases in Lombardy. 
 
Contact data collected after April 16, 2020 were excluded to avoid biases caused by delays in development of 
symptoms, reporting, and in seroconversion of infected individuals. The performed analysis is based on the 
serological test results obtained by May 25, 2020 and on the linelist of all COVID-19 cases detected in the region, 
as updated on June 8, 2020. In this study, we selected only contacts belonging to clusters with complete testing, 
i.e. clusters whose contacts all received at least one between a valid RT-PCR result or a valid serological result 
[1]. Clusters with case contacts with inconclusive serological results were excluded by the proposed analysis.  
 
A close case contact was defined as either of the following: 
- a person living in the same household as a COVID-19 confirmed case; 
- a person having had face-to-face interaction with a COVID-19 confirmed case; 
- a person who was in a closed environment (e.g. classroom, meeting room, hospital waiting room) with a 
COVID-19 confirmed case at a distance of less than 2 meters for more than 15 minutes; 
- a healthcare worker or other person providing direct care for a COVID-19 confirmed case, or laboratory 
workers handling specimens from a COVID-19 confirmed case without recommended personal protective 
equipment (PPE) or with a possible breach of PPE; 
- a contact in an aircraft sitting within two seats (in any direction) of a COVID-19 confirmed case, travel 
companions or persons providing care, and crew members serving in the section of the aircraft where the index 
case was seated; passengers seated in the entire section or all passengers on the aircraft were considered close 
contacts of a confirmed case when severity of symptoms or movement of the case indicated more extensive 
exposure. 
Confirmed cases were defined as subjects with positive laboratory confirmation via RT-PCR assays for virus 
causing of SARS-CoV-2 infection, irrespective of clinical signs and symptoms. 
 
 
A cluster of contacts was defined as the set of contacts identified by one positive index case. Contact tracing 
activities were carried out through standardized epidemiological investigations of positive cases (or of their 
parents/relatives) to determine the history of individuals’ exposure. The exposure period was initially defined as 
the time interval ranging from 14 days before to 14 days after the symptom onset of an index case. Following 
guidelines from WHO [2], after March 20 the time interval was changed from 2 days before to 14 days after the 
symptom onset of the index case.  
 
Confirmation of cases was obtained with nasal swabs (UTM viral transport ®, Copan Italia S.p.a) with at least two 
real-time RT-PCR assays targeting different genes (E and RdRp) of SARS-CoV-2 [3,4]. In addition, a novel 
quantitative real-time RT-PCR targeting an additional SARS-CoV-2 gene (M) was developed (details provided 
upon request).  From February 21 to February 25, all contacts were tested for the presence of viral genome on 
their nasopharyngeal trait. From February 26 onward, testing was applied only to symptomatic contacts due to 
limited availability of testing capacity. From March 20, positivity of nasal swabs was also ascertained from a test 
that sought a single gene. Individuals with inconclusive tests were swabbed again and re-tested to resolve the 
diagnosis.  
 
On April 16, the Lombardy Region initiated a large-scale serological screening to evaluate the prevalence of 
SARS-CoV-2 infection among all remaining untested contacts. Serological screening included both symptomatic 
and asymptomatic case contacts identified through contact tracing activities without history of a swab for SARS-
CoV-2. A relatively small number of serological tests were administered to individuals already tested by RT-PCR 
(n=627 in our sample). The test used to detect SARS-CoV-2 IgG antibodies is the LIAISON® SARS-CoV-2 test [5,6]. 
The LIAISON® SARS-CoV-2 test employs magnetic beads coated with S1 & S2 antigens. The antigens used in the 
tests are expressed in human cells to achieve proper folding, oligomer formation, and glycosylation, providing 
material similar to the native spikes. This strategy ensures that the antigen-antibody complex forms with the 
required specificity. The S1 and S2 proteins are both targets to neutralizing antibodies. The test provides the 
detection of IgG antibodies against S1/S2 antigens of SARS-CoV-2 and the detection of neutralizing antibodies 
with >97% specificity and >94% sensitivity at 15 days from diagnosis [5,6] and validated against Plaque 
Reduction Neutralization Test (PRNT) [5]. A negative result (<12 AU/mL) indicates the absence or a very low 
level of IgG antibodies directed against the virus; this occurs in the absence of infection or during the incubation 
period or in the early stages of the disease. An inconclusive result (12-15 AU/mL) can be interpreted as both a 
false positive or a false negative and suggests repeating the exam after a week. A positive result (>15 AU/mL) 
indicates the presence of IgG antibodies and therefore a past infection with SARS-CoV-2.   
 
Statistical analysis 
 
Contact tracing data combined with test results and outcomes of close contacts associated with each index case 
were used to estimate the SARS-CoV-2 infection fatality rate (IFR). The IFR was estimated for male and female 
individuals separately and for five age groups (0-19 years, 20-49 years, 50-59 years, 60-69 years, 70-79 years, 
80+ years) in two distinct epidemic phases (before and after March 16, 2020) and for patients affected by 
cardiovascular comorbidities (including hypertension) and patients with no comorbidities. The IFR was 
computed as the proportion of deaths among the total number of infected individuals for each considered 
strata. Exact binomial test was used to estimate confidence intervals.  
 
To investigate IFR risk factors, we used a generalized linear model (GLM with logit link), using the outcome of 
positive close contacts as a binary response variable (i.e. death vs. survival) and considering the following 
covariates: 
• the age group of the contact; as no deaths were found below 50 years of age, four age groups were 
considered in this case: 0-59 years, 60-69 years, 70-79 years, 80+ years. 
• the sex of the contact; 
• a categorical variable defining whether: 1) the contact was presenting at least one cardiovascular 
comorbidity, including hypertension; 2) the contact was not presenting cardiovascular comorbidities 
but was presenting at least one of the following comorbidities: respiratory, oncological, metabolic 
(including diabetes); 3) no comorbidities were known for the contact; 
• a binary variable defining whether the date of identification of the index case associated to the contact 
was prior or posterior to March 16, 2020; this date represents the median date of confirmation among 
index cases in the selected clusters (i.e. those with complete testing). 
 
Regression models including interactions between covariates or considering the number of comorbidities 
affecting a contact were ruled out when compared to model described above on the basis of likelihood ratio 
tests. Regression models using a numeric variable for the number of comorbidities or a binary variable for the 
presence of each type of comorbidity instead of the above described categorical variable were ruled out on the 
basis of the Akaike information criterion. 
 
Risk ratios of death after infection were computed given the covariates, using the generalized linear model 
described above. Resulting means were compared by Tukey post-hoc test. The statistical analysis was 
performed using R (version 3.6). 
 
Finally, in the analyzed sample (Table S1), 41.9% (137/327) contacts tested by both RT-PCR and serology 
resulted negative to RT-PCR and positive to serology. This result may be due to a variety of factors including 
false positive results from RT-PCR, false negative results from serology, late PCR testing of SARS-CoV-2 
infections, transmission occurred outside the analyzed clusters. Although our data are not appropriate to 
evaluate the accuracy of PCR and serological tests, we performed a sensitivity analysis to explore to explore to 
what extent false negative PCR results can affect our estimates on the IFR.  To do this, we computed the IFR 
resulting form 10,000 simulations where, a random sample of 41.9% contacts who were RT-PCR negative 
contacts and were not tested with serology (namely 732) is assumed to be  positive to SARS-CoV-2. In this case 
the IFR results 2.04% (95%CI 1.57-2.60%) instead of the 2.2% (95%CI 1.69-2.81%),obtained in our baseline 
analysis. 
 
Supplementary tables and figures 
 
 SARS-CoV-2 positive Deaths Relative risk 
Sex    
Females 1604 29 reference 
Males 1220 33 1.81 (95%CI 1.03-3.16) 
Age    
80+ 158 29 reference 
0-59y 1837 3 0.03 (95%CI 0.01-0.1) 
60-69y 494 7 0.14 (95%CI 0.05-0.32) 
70-79y 335 23 0.5 (95%CI 0.27-0.89) 
Comorbidity    
None 113 1 reference 
Cardiovascular  316 51 5.64 (95%CI 1.17-55.27) 
Other comorbity 60 1 0.93 (95%CI 0.04-20.55) 
Unknown 2335 9 0.36 (95%CI 0.06-6.42) 
Epidemic period    
Before March 18,2020 1423 42 reference 
After March 18,2020 1358 18 0.38 (95%CI 0.2-0.69) 
Unknown 43 2 3.09 (95%CI 0.43-10.94) 
Table S1. Estimated relative risks of death after SARS-CoV-2 infection as obtained by a generalized linear mixed-
effects model where the fatal outcome is used as the response variable and sex, age group, comorbidities, and 
epidemic period are considered as regressors.  
 
RT-PCR Serological assay (IgG) Total 
Performed Not performed 1,364  
       Positive        - 632  
Not performed Performed 3,493  
       -        Positive 1,755  
Performed Performed 627  
       Positive        Negative 5  
       Negative        Positive 137 
       Positive        Positive 295 
 
Table S2. Sample description. In Lombardy, from February 26 onward, only symptomatic contacts of COVID-19 
confirmed cases were tested with RT-PCR. Out of 1,991 RT-PCR tests, 1,947 were conducted after February 26.  
  
 
Figure S1. Age-specific estimates (mean) of IFR in male and female subjects (top) and during two epidemic 
periods (bottom). Horizontal lines represent 95% confidence intervals computed by exact binomial tests. 
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Figure S2. Comparison of the age distribution of analyzed close contacts (darker bars represent SARS-CoV-2 
positive individuals) with the age distribution of the Lombardy population in 2019, as reported by the Italian 
National Institute of Statistics [7]  
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